2023-506230-71-01RecruitingPhase 4
Vaccination in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on the immunogenicity of herpes-zoster vaccine (Shingrix) and protection against infection (HZ-REUMA)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 6 Nov 2023 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 1 (estimated)
- First submitted
- 23 Aug 2023
- Start date
- 17 Dec 2024
- Lead sponsor
- Region Skane Skanes Universitetssjukhus
- EU CT number
- 2023-506230-71-01
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 1
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Region Skane Skanes Universitetssjukhus | Lund | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.